Jan 14, 2020 / 05:30PM GMT
Tycho W. Peterson - JP Morgan Chase & Co, Research Division - Senior Analyst
Okay. We're going to go ahead and get started. I'm Tycho Peterson from the Life Science team. It's my pleasure to introduce Charles River Labs. We'll do a breakout right after in the Olympic room.
With that, let me turn it over to Jim Foster.
James C. Foster - Charles River Laboratories International, Inc. - Chairman, CEO & President
Thanks, Tycho. Good morning. Always a pleasure to be here. The safe harbor, Reg G and quiet period statements. So we are the leading nonclinical CRO. Just a few stats. We worked on 85% of the drugs that were approved last year. We're very proud of that. Our revenues have doubled. In the last 5 years. We are -- sort of total collective marketplace is north of $15 billion and growing nicely, so we have a long runway. Our growth rate is in the high single digits these days. We -- our Early Discovery business has worked on 80 novel compounds for our clients. So we've done target identification for 80 compounds, we're quite proud of that.
Charles River Laboratories International Inc at JPMorgan Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot